114
Views
8
CrossRef citations to date
0
Altmetric
Brief Report

Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes

, , , , , , , & show all
Pages 1775-1781 | Accepted 21 May 2007, Published online: 25 Jun 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Anthony H. Barnett. (2010) Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Current Medical Research and Opinion 26:6, pages 1333-1342.
Read now

Articles from other publishers (7)

A. Avogaro, M. Federici, J. Betteridge, R. Bonadonna, I. W. Campbell, G. H. Schernthaner, B. Staels, E. Farinaro & G. Crepaldi. (2014) Which is the eligible patient to be treated with pioglitazone? The expert view. Journal of Endocrinological Investigation 34:10, pages 781-787.
Crossref
Kylie Kavanagh, Kathleen K. Brown, Mandy L. Berquist, Li Zhang & Janice D. Wagner. (2010) Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor–γ agonist use in prediabetes. Metabolism 59:6, pages 914-920.
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter (posthumous). 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jochen Seufert. (2009) The backbone of oral glucose-lowering therapy: time for a paradigm shift?. Fundamental & Clinical Pharmacology 23:6, pages 651-667.
Crossref
Thomas SchöndorfEfstrathios KaragiannisRichard E.K. PosseldtThomas ForstAndreas Pfützner. (2009) Competact, a Fixed Combination of Pioglitazone and Metformin, Improves Metabolic Markers in Type 2 Diabetes Patients with Insufficient Glycemic Control by Metformin Alone—Results from a Post-Marketing Surveillance Trial Under Daily Routine Conditions. Diabetes Technology & Therapeutics 11:6, pages 379-383.
Crossref
Ian W Campbell. (2009) Review: Durable glycaemia — the promised land. The British Journal of Diabetes & Vascular Disease 9:2, pages 53-63.
Crossref
Mark Stolar. (2009) Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. Clinical Medicine. Therapeutics 1, pages CMT.S2370.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.